Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review.
OBJECTIVE
To characterize the adverse effects of treatment with selective serotonin reuptake inhibitors (SSRIs) started in children under age 7 yr.


METHODS
We conducted a retrospective review of medical records for all children who had begun treatment with an SSRI under age 7 at an academic psychiatry department in Boston.


RESULTS
Thirty-nine children (26 males, 13 females) met the inclusion criteria. Mean age at start of treatment was 5.9 +/- 0.8 yr, and median treatment duration was 5.0 months. The target diagnoses for SSRI treatment were anxiety disorders in 54%, depressive disorders in 23%, and both anxiety and depressive disorders in 20% of patients. There were no reports of suicidal ideation or attempt. No children were medically or psychiatrically hospitalized for adverse effects (AEs). Eleven patients (28%) reported an AE of at least moderate severity; 7 (18%) discontinued the SSRI due to the AE. Six patients discontinued due to behavioral activation and 1 due to gastrointestinal upset. The median time to onset of an AE was 23 days, and median resolution was 19 days from onset.


CONCLUSIONS
The high rate of adverse effects, especially activation, in this sample argues for continued caution in using SSRIs in young children. Controlled trials are warranted.
Zuckerman
Marcia L
ML
Psychopharmacology Program, Department of Psychiatry, Children's Hospital Boston and Harvard Medical School, MA 02115, USA.
Vaughan
Brigid L
BL
Whitney
Jane
J
Dodds
Alice
A
Yakhkind
Aleksandra
A
MacMillan
Carlene
C
Raches
Darcy
D
Pravdova
Iva
I
DeMaso
David Ray
DR
Beardslee
William R
WR
Gonzalez-Heydrich
Joseph
J
D000342:Affective Symptoms / Q000139:chemically induced; D000367:Age Factors; D000374:Aggression / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D020022:Genetic Predisposition to Disease; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D017367:Selective Serotonin Reuptake Inhibitors